Genentech/OSI Tarceva NDA Filing Will Wait For Phase III Monotherapy Data
OSI hopes to be in a position to file a Tarceva NDA in early 2004, when data in refractory non-small cell lung cancer patients is expected
OSI hopes to be in a position to file a Tarceva NDA in early 2004, when data in refractory non-small cell lung cancer patients is expected